Skip to main content

Volume 21 Supplement 1

Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium

Proceedings

Publication of this supplement has been supported by the SJIA Foundation. The articles have undergone the journal's standard peer review process for supplements.

Virtual16-18 February 2022

Conference website

  2. Currently, the criteria used to classify patients with SJIA are different from those used for AOSD. However, it has been recognized that the existing terms are too narrow, subdividing the Still’s population un...

    Authors: Peter A. Nigrovic, Fabrizio de Benedetti, Yukiko Kimura, Daniel J. Lovell and Sebastiaan J. Vastert
    Citation: Pediatric Rheumatology 2024 21(Suppl 1):114
    Content type: Meeting report Published on:

  3. Although the introduction of the IL-1 and IL-6 inhibiting biologics in 2012 has revolutionized the treatment and markedly improved outcomes for many patients with SJIA, about 20% of these patients continue to ...

    Authors: Grant Schulert, Sebastiaan J. Vastert and Alexei A. Grom
    Citation: Pediatric Rheumatology 2024 21(Suppl 1):87
    Content type: Meeting report Published on:

  4. The substantial morbidity and mortality associated with refractory systemic JIA underlies the need for new treatment approaches. However, progress in this area has been limited by the difficulty of enrolling t...

    Authors: Fabrizio de Benedetti, Alexei A. Grom and Hermine Brunner
    Citation: Pediatric Rheumatology 2024 21(Suppl 1):150
    Content type: Meeting report Published on:

  5. Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, the...

    Authors: Scott W. Canna and Fabrizio De Benedetti
    Citation: Pediatric Rheumatology 2024 21(Suppl 1):79
    Content type: Meeting report Published on:

  6. It has been increasingly recognized that there is a subset of patients with refractory systemic JIA, who have failed all available medications and may benefit from HSCT. The increasing experience with HSCT in ...

    Authors: Alexei A. Grom, Scott W. Canna, Rolla F. Abu-Arja, Rashmi Sinha, Luciana Peixoto, Elvira Cannizzaro, Shanmuganathan Chandrakasan, Kyla Driest, Rebecca Marsh, Bénédicte Neven, Karen Onel, Sampath Prahalad, Susan Prockop, Pierre Quartier, Johannes Roth, Grant Schulert…
    Citation: Pediatric Rheumatology 2024 21(Suppl 1):86
    Content type: Meeting report Published on:

Official journal of

  • New Content Item
Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.8
    5-year Journal Impact Factor: 2.8
    Source Normalized Impact per Paper (SNIP): 0.966
    SCImago Journal Rank (SJR): 0.835

    Speed 2024
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 94

    Usage 2024
    Downloads: 1,320,783
    Altmetric mentions: 320

Pediatric Rheumatology

ISSN: 1546-0096